公开(公告)号：US20060246145A1

公开(公告)日：2006-11-02

申请号：US11371118

申请日：2006-03-08

Applicant: James Chang ,  Patrick Hughes ,  Chin-Ming Chang

Inventor： James Chang ,  Patrick Hughes ,  Chin-Ming Chang

IPC: A61K9/50 ,  B01J13/04 ,  B01J13/02 ,  A61K9/16

CPC classification number: A61K31/5575 ,  A61K9/0048 ,  A61K9/0051 ,  A61K9/107 ,  A61K9/1075 ,  A61K9/146 ,  A61K9/1647 ,  A61K9/1694 ,  A61K31/165 ,  A61K47/34 ,  B01J13/04 ,  B01J13/06

Abstract: Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.

Abstract translation: 生物相容的微粒包括眼科活性的环状脂质组分和可生物降解的聚合物，当放置在结膜下空间中时，有效地促进环状脂质成分延长眼睛部分的时间。 环状脂质组分可与可生物降解的聚合物基质相结合，例如两种可生物降解聚合物的基质。 或者，环状脂质组分可以被聚合物组分包封。 本发明的微粒包括水包油乳化微粒。 结膜下施用的微粒可用于治疗或减少眼部疾病如青光眼或年龄相关性黄斑变性的至少一种症状。

公开(公告)号：US20060176528A1

公开(公告)日：2006-08-10

申请号：US11053370

申请日：2005-02-08

Applicant: John Dalrymple ,  James Chang

Inventor： John Dalrymple ,  James Chang

IPC: G03F3/08

CPC classification number: H04N1/6058

Abstract: Embodiments of the present invention comprise methods and systems for color gamut mapping.

Abstract translation: 本发明的实施例包括用于色域映射的方法和系统。

公开(公告)号：US20060141049A1

公开(公告)日：2006-06-29

申请号：US11354415

申请日：2006-02-14

Applicant: Robert Lyons ,  James Chang ,  John Trogden ,  Scott Whitcup

Inventor： Robert Lyons ,  James Chang ,  John Trogden ,  Scott Whitcup

IPC: A61K31/728 ,  A61K31/695 ,  A61K9/14

CPC classification number: A61K9/0048 ,  A61K31/56 ,  A61K31/573 ,  A61K47/36

Abstract: Triamcinolone compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time.

Abstract translation: 提供曲安奈德组合物，以及使用这些组合物的方法，其用于注射到人眼的玻璃体中。 这样的组合物可以包括以治疗有效量存在的曲安奈德颗粒，粘度诱导组分和水性载体组分。 组合物在0.1 /秒的剪切速率下具有至少约10cps或约100cps的粘度。 在优选的实施方案中，粘度在约80,000cps至约300,000cps的范围内。 组合物有利地将曲安奈德颗粒悬浮较长时间。

公开(公告)号：US20060012811A1

公开(公告)日：2006-01-19

申请号：US10892845

申请日：2004-07-16

Applicant: John Dalrymple ,  James Chang

Inventor： John Dalrymple ,  James Chang

IPC: G06F15/00

CPC classification number: H04N1/6016

Abstract: Systems and methods for dynamically limiting total colorant coverage in multi-colorant rendering. Two polyhedra are defined: one contains all the colors that exceed the total colorant limit, and another is within the colorant limit that contains the results of the colorant limitation process. Data is received to identify a specified contone color, which is processed to decide whether it is inside one of the polyhedra. If the specified contone color is not within either polyhedra, the specified contone color is used in the rendering process. Alternatively, if the specified contone color is within one of the polyhedra, the value representing the specified contone color is compressed into the second polyhedra volume to obtain a resultant contone color that is used in the rendering process.

Abstract translation: 在多着色剂渲染中动态限制着色剂总重量的系统和方法。 定义了两个多面体：一个包含超过总着色剂极限的所有颜色，另一个包含着色剂界限，其中包含着色剂限制过程的结果。 收到数据以识别指定的连字符颜色，该颜色被处理以决定是否在多面体之一内。 如果指定的连字符颜色不在多面体内，则在渲染过程中将使用指定的连字符颜色。 或者，如果指定的连字符颜色在多面体之一内，则表示指定连续色的颜色的值被压缩到第二多面体体积中，以获得在渲染过程中使用的合成连续色。

公开(公告)号：US20050250737A1

公开(公告)日：2005-11-10

申请号：US11091977

申请日：2005-03-28

Applicant: Patrick Hughes ,  Laurent Delahaye ,  Michele Boix ,  James Chang ,  Robert Lyons

Inventor： Patrick Hughes ,  Laurent Delahaye ,  Michele Boix ,  James Chang ,  Robert Lyons

IPC: A61K9/00 ,  A61K31/573 ,  A61K31/724 ,  A61K47/36

CPC classification number: A61K9/0048 ,  A61K31/573 ,  A61K47/36 ,  A61K47/40

Abstract: Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in amounts effective in providing a desired therapeutic effect when placed in an eye, and one or more retinal friendly excipients that have a reduced toxicity relative to benzyl alcohol or polysorbate 80. In certain compositions, the excipient component of the compositions comprises one or more cyclodextrins or cyclodextrin derivatives. Methods of using the compositions to treat ocular conditions are also described.

Abstract translation: 描述适于施用于人或动物的眼睛内部的药物组合物。 本发明组合物包括一种或多种有效提供相对于现有眼内眼用组合物的毒性降低的成分。 本发明的组合物包含一种或多种治疗剂，其用量在置于眼中时可提供所需的治疗效果，以及一种或多种视黄醛友好的赋形剂，其相对于苯甲醇或聚山梨酸酯80具有降低的毒性。在某些组合物中，赋形剂 组合物的组分包含一种或多种环糊精或环糊精衍生物。 还描述了使用组合物治疗眼睛病症的方法。

公开(公告)号：US20050244474A1

公开(公告)日：2005-11-03

申请号：US11118288

申请日：2005-04-29

Applicant: Glenn Huang ,  Thierry Nivaggioli ,  Lon Spada ,  Hiroshi Sugimoto ,  Wendy Blanda ,  James Chang ,  Orest Olejnik

Inventor： Glenn Huang ,  Thierry Nivaggioli ,  Lon Spada ,  Hiroshi Sugimoto ,  Wendy Blanda ,  James Chang ,  Orest Olejnik

IPC: A61K9/00 ,  A61K31/00 ,  A61K31/573 ,  A61K45/06 ,  A61F2/00

CPC classification number: A61K9/0051 ,  A61K9/0092 ,  A61K31/573 ,  A61K31/58 ,  A61K45/06 ,  A61K2300/00

Abstract: Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.

Abstract translation: 生物相容性眼内植入物包括彼此相关的类固醇和聚合物，以促进类固醇进入眼睛大于约两个月的时间。 类固醇可以与可生物降解的聚合物基质相关联，例如两种可生物降解聚合物的基质。 或者，类固醇可以与具有一个或多个开口有效以允许类固醇释放到外部环境中的聚合物涂层相关联。 植入物可以放置在眼睛中以治疗一种或多种眼睛状况。 类固醇从植入物中释放超过约两个月，可能会释放超过几年。

公开(公告)号：US20050073769A1

公开(公告)日：2005-04-07

申请号：US10679523

申请日：2003-10-06

Applicant: Lucas Lee ,  YuNang Zai ,  James Chang ,  JiaHong Shu ,  PeiKoh Lee

Inventor： Lucas Lee ,  YuNang Zai ,  James Chang ,  JiaHong Shu ,  PeiKoh Lee

IPC: G11B21/02 ,  G11B21/22

CPC classification number: G11B21/22

Abstract: A device for detecting an actuator assembly parking error when a disc drive is powered on includes a magnetic latch attached to the actuator assembly and a latch pin assembly electrically connected to a base plate in the disc drive, where the latch pin assembly is positioned to contact the magnetic latch only when the actuator's read/write head is positioned over a parking zone on the disc. A detection module is electrically connected to the magnetic latch and thus is able to detect whether or not the magnetic latch is contacting the latch pin assembly when the disc drive is powered on. A method for detecting an actuator assembly parking error includes powering on the disc drive, determining whether the magnetic latch has electrical contact with the latch pin assembly, and reporting a parking error if the magnetic latch does not have electrical contact with the latch pin assembly.

公开(公告)号：US20050062491A1

公开(公告)日：2005-03-24

申请号：US10963639

申请日：2004-10-14

Applicant: Lawrence Burns ,  Leonard Dauphinee ,  Ramon Gomez ,  James Chang

Inventor： Lawrence Burns ,  Leonard Dauphinee ,  Ramon Gomez ,  James Chang

IPC: G01R31/26 ,  G01R31/30 ,  G01R31/317 ,  H01L21/66 ,  H03F3/21 ,  H04N5/44 ,  H04N5/52 ,  H04N7/10 ,  G01R31/02

CPC classification number: H01L22/20 ,  G01R31/2607 ,  G01R31/30 ,  G01R31/31723 ,  H03F3/211 ,  H04N5/4446 ,  H04N5/52 ,  H04N7/102

Abstract: A method and system for monitoring and compensating the performance of an operational circuit is provided. The system includes one or more integrated circuit chips and a controller. Each integrated circuit chip includes one or more operational circuits, each operational circuit having at least one controllable circuit parameter. Each integrated circuit chip also includes a process monitor module at least partially constructed thereon. The controller is coupled to each process monitor module and to each operational circuit. The controller includes logic for evaluating the performance of an operational circuit based on data obtained from process monitor module and operational circuit related data stored in a memory. Based on the evaluation, the controller determines whether any deviations from desired or optimal performance of the circuit exist. If deviations exist, the controller generates a control signal to initiate adjustments to the operational circuit to compensate for the deviations.

Abstract translation: 提供了一种用于监测和补偿操作电路的性能的方法和系统。 该系统包括一个或多个集成电路芯片和控制器。 每个集成电路芯片包括一个或多个操作电路，每个操作电路具有至少一个可控电路参数。 每个集成电路芯片还包括至少部分地构建在其上的过程监控模块。 控制器耦合到每个过程监控模块和每个操作电路。 控制器包括用于基于从存储在存储器中的过程监视模块和操作电路相关数据获得的数据来评估操作电路的性能的逻辑。 基于评估，控制器确定是否存在与电路的期望或最佳性能的任何偏差。 如果存在偏差，则控制器产生控制信号以启动对运算电路的调整以补偿偏差。

公开(公告)号：US20050059583A1

公开(公告)日：2005-03-17

申请号：US10927857

申请日：2004-08-27

Applicant: Andrew Acheampong ,  Diane Tang-Liu ,  James Chang ,  David Power

Inventor： Andrew Acheampong ,  Diane Tang-Liu ,  James Chang ,  David Power

IPC: A61K9/00 ,  A61K38/13 ,  A61P27/02

CPC classification number: A61K38/13 ,  A61K9/0048 ,  A61K9/107 ,  A61K47/02 ,  A61K47/10 ,  A61K47/22 ,  A61K47/32 ,  A61K47/44

Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.

Abstract translation: 治疗人或动物眼睛的方法包括向人或动物眼睛施用包含水，疏水组分和环孢菌素组分的乳液形式的组合物，其治疗有效量小于0.1重量％ 的组成。 环孢菌素组分与疏水组分的重量比小于0.8。

公开(公告)号：US20050004074A1

公开(公告)日：2005-01-06

申请号：US10613097

申请日：2003-07-01

Applicant: Robert Lyons ,  James Chang

Inventor： Robert Lyons ,  James Chang

IPC: A61K9/00 ,  A61K31/557 ,  A61K31/724

CPC classification number: A61K9/0048 ,  A61K31/557 ,  A61K31/724

Abstract: This invention relates to a method of reducing an irritating or adverse side effect associated with the topical use of an active ophthalmic drug comprising incorporating an effective amount of a cyclodextrin or cyclodextrin derivative into a formulation to complex the active drug such that the concentration of the free active drug is reduced below a tolerable threshold, and incorporating an effective amount of a viscosity increasing agent in said formulation such that the bioavailability of said drug is high enough to be therapeutically effective, wherein the cyclodextrin or cyclodextrin derivative is not required to solubilize the active drug. Another aspect of this invention relates to topical ophthalmic formulations comprising an active drug, a cyclodextrin or cyclodextrin derivative, and a viscosity-enhancing agent, in effective amounts as stated above.